Clinical Characteristics and Prognoses of Mucormycosis in Four Children
DOI: https://doi.org/10.2147/idr.s462725
2024-05-19
Infection and Drug Resistance
Abstract:Li Li, 1 Xiaoli Zhen, 2 Wenjian Wang 1 1 Department of Respiratory Diseases, Shenzhen Children's Hospital, Shenzhen, Guangdong, People's Republic of China; 2 Department of Radiology, Shenzhen Children's Hospital, Shenzhen, People's Republic of China Correspondence: Wenjian Wang, Department of Respiratory Diseases, Shenzhen Children's Hospital, No. 7019 Yitian Road, Futian District, Shenzhen, Guangdong, People's Republic of China, Email Background: Mucormycosis is a fatal invasive fungal infection that commonly affects immunocompromised children. The aim of our study was to investigate the clinical manifestations, treatments, and prognosis of pediatric patients with mucormycosis. Methods: We conducted a retrospective search in Shenzhen Children's Hospital from July 2013 to July 2023 for all patients with mucormycosis. The clinical manifestation, pathogen detection, radiology, treatments, and prognosis were analyzed. Results: Four cases were identified. Underlying conditions included acute myeloid leukemia with myeloid sarcoma (n = 1), thalassemia (post-allogeneic hematopoietic stem cell transplantation; n = 1), systemic lupus erythematosus (n = 1), and bilateral nephroblastoma (post-bilateral nephrectomy; n = 1). Two patients were disseminated mucormycosis, one case was pulmonary mucormycosis, and one case was cerebral mucormycosis. Fever, cough, and dyspnea were the main clinical symptoms of pulmonary mucormycosis, headache was the main clinical symptom of cerebral mucormycosis. Lung CT findings included consolidation, multiple nodules, halo sign, air crescent sign, and pleural effusion. The contrast-enhanced CT showed pulmonary artery and pulmonary vein occlusions in two patients and pseudoaneurysm in two patients. Amphotericin B formulations were administered as first-line therapy in all cases; in three cases, Triazole was administered in combination with amphotericin B. Conclusion: Mucormycosis is a life-threatening disease involving multiple systems. Aorta pseudoaneurysm is a rare and fatal complication, enhanced CT can assist in diagnosis. Early diagnosis and appropriate therapeutic strategies are needed. Keywords: children, immunocompromised, mucormycosis, pseudoaneurysm Mucormycosis is caused by Mucoraceae , which are ubiquitous in the environment and have become important pathogens among immunocompromised children. The underlying diseases in mucormycosis include hematological and solid organ tumors, hematopoietic stem cell and solid organ transplants, immunosuppressive therapy, and neutropenia. 1 Mucormycosis includes sinusitis, cutaneous, pulmonary, gastrointestinal, disseminated, and other uncommon rare forms. 2 The involvement of two or more non-contiguous sites is defined as disseminated mucormycosis. It is rare in children. Mucorales can invade blood vessels and disseminate through hematogenous routes. Prakash H reported that 13% of mucormycosis patients present with disseminated disease. 3 In this study, we aimed to analyze the clinical data of four patients with mucormycosis in our hospital to provide helpful information for clinical research. Pediatric patients diagnosed with mucormycosis from July 2013 to July 2023 at Shenzhen Children's Hospital were enrolled in the study. The electronic medical records, imaging, and pathogen information were collected for all cases. Metagenomic next-generation sequencing was performed on the four patients. Specimens included bronchoalveolar lavage fluid from one patient, CSF-cerebrospinal fluid and peripheral blood from one patient, peripheral blood and bronchoalveolar lavage fluid from one patient, and hydrothorax and bronchoalveolar lavage fluid from one patient. All aspects of the study were performed in accordance with the ethical standards of the institutional research committee and the 1964 Helsinki Declaration. The study protocol was approved by the Ethical Committee of Shenzhen Children's Hospital (number 201601304). Written informed consent was obtained from all of the participants guardians. Four pediatric cases of mucormycosis were included in the study. The median age was 10.2 years (range, 5.6–11.9 years). Underlying conditions included relapsed acute myeloid leukemia (AML) with myeloid sarcoma (n = 1), thalassemia (post-allogeneic hematopoietic stem cell transplantation; n = 1), systemic lupus erythematosus (SLE) (n = 1), and bilateral nephroblastoma (post bilateral nephrectomy; n = 1). Three patients were undergoing chemotherapy, and one patient underwent hematopoietic stem cell transplantation (HSCT). The median duration of neutropenia before mucormycosis was 29.5 days (range, 0–201 days). The patient characteristics were in Table 1. Table 1 -Abstract Truncated-
pharmacology & pharmacy,infectious diseases